Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Kymera Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -341.8%. For fiscal 2025 it was -794.0%, against -475.6% the year before. The highest annual figure on record is -134.0% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -794.0% | −318.5 |
| FY2024 | Dec 31, 2024 | -475.6% | −288.6 |
| FY2023 | Dec 31, 2023 | -187.0% | +143.6 |
| FY2022 | Dec 31, 2022 | -330.6% | −193.0 |
| FY2021 | Dec 31, 2021 | -137.6% | −3.6 |
| FY2020 | Dec 31, 2020 | -134.0% | +1271.8 |
| FY2019 | Dec 31, 2019 | -1405.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -94.2% | +573.4 |
| Q1 FY2026 | Mar 31, 2026 | -201.5% | +95.3 |
| Q4 FY2025 | Dec 31, 2025 | -3030.7% | −2073.8 |
| Q3 FY2025 | Sep 30, 2025 | -2973.0% | −1302.7 |
| Q2 FY2025 | Jun 30, 2025 | -667.6% | −503.6 |
| Q1 FY2025 | Mar 31, 2025 | -296.7% | +175.3 |
| Q4 FY2024 | Dec 31, 2024 | -956.9% | −926.9 |
| Q3 FY2024 | Sep 30, 2024 | -1670.3% | −552.2 |
| Q2 FY2024 | Jun 30, 2024 | -164.0% | +71.0 |
| Q1 FY2024 | Mar 31, 2024 | -472.0% | −39.7 |
| Q4 FY2023 | Dec 31, 2023 | -30.0% | +186.0 |
| Q3 FY2023 | Sep 30, 2023 | -1118.2% | −667.9 |
| Q2 FY2023 | Jun 30, 2023 | -235.0% | +114.7 |
| Q1 FY2023 | Mar 31, 2023 | -432.4% | −51.1 |
| Q4 FY2022 | Dec 31, 2022 | -216.0% | +5.9 |
| Q3 FY2022 | Sep 30, 2022 | -450.2% | −309.7 |
| Q2 FY2022 | Jun 30, 2022 | -349.6% | −216.5 |
| Q1 FY2022 | Mar 31, 2022 | -381.3% | −311.3 |
| Q4 FY2021 | Dec 31, 2021 | -221.9% | −122.7 |
| Q3 FY2021 | Sep 30, 2021 | -140.5% | −85.6 |
| Q2 FY2021 | Jun 30, 2021 | -133.2% | +292.3 |
| Q1 FY2021 | Mar 31, 2021 | -69.9% | +249.0 |
| Q4 FY2020 | Dec 31, 2020 | -99.2% | +528.9 |
| Q3 FY2020 | Sep 30, 2020 | -55.0% | +1147.2 |
| Q2 FY2020 | Jun 30, 2020 | -425.5% | – |
| Q1 FY2020 | Mar 31, 2020 | -318.9% | – |
| Q4 FY2019 | Dec 31, 2019 | -628.1% | – |
| Q3 FY2019 | Sep 30, 2019 | -1202.1% | – |
See a number that looks wrong?